Sugi Predict

Sugi Predict / Compounds / SCHEMBL4034002

SCHEMBL4034002

SCHEMBL4034002

O=C(NCCc1ccccc1)C1CCNCC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.60
▸ MC4R P32245 1/20 0.59
▸ ALDH1A1 P00352 3/20 0.59
▸ GAA P10253 2/20 0.59
▸ TSHR P16473 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ POLB P06746 4/20 0.57
▸ TAAR1 Q96RJ0 4/20 0.57
▸ KMT2A Q03164 4/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ LMNA P02545 1/20 0.56
▸ ALOX12 P18054 1/20 0.56
▸ RECQL P46063 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ EPHX2 P34913 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12420662 0.91 MTNR1A (0.56) CYP2C19MC4RALDH1A1GAATSHR
SCHEMBL23417495 0.89 CYP2C19 (0.68) CYP2C19ALDH1A1GAATSHRL3MBTL1
Tert-Butyl Formate SCHEMBL28309483 0.87 CYP2C19 (0.51) CYP2C19MC4RALDH1A1GAATSHR
SCHEMBL5081412 0.85 KMT2A (0.59) ALDH1A1L3MBTL1POLBTAAR1KMT2A
SCHEMBL12936131 0.85 HSD17B10 (0.58) CYP2C19ALDH1A1KDM4EPOLBSMN1; SMN2
SCHEMBL14615541 0.85 SLC6A4 (0.51) ALDH1A1SMN1; SMN2
SCHEMBL3392745 0.84 ALDH1A1 (0.74) CYP2C19ALDH1A1TSHRL3MBTL1POLB
SCHEMBL13138659 0.84 ALDH1A1 (0.74) CYP2C19ALDH1A1TSHRL3MBTL1POLB
SCHEMBL7272444 0.84 TAAR1 (0.64) CYP2C19ALDH1A1GAATSHRL3MBTL1
SCHEMBL526330 0.84 ALDH1A1 (0.73) MC4RALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275723-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-15 — — US disclosed
US-20240400546-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-12-05 — — US disclosed
US-20240300938-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-09-12 — — US disclosed
US-11970486-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-04-30 — — US disclosed
US-20240124435-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-04-18 — — US disclosed
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 — — CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
CN-110099898-B Compounds and uses thereof 优曼尼蒂治疗公司 2023-07-25 — — CN disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 — — WO disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 — — WO disclosed
EP-3529245-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2019-08-28 — — EP disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 — — WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 — — WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 — — WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 — — WO disclosed
EP-1501467-A4 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2009-08-19 — — EP disclosed
EP-1501467-A2 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION Bristol-Myers Squibb Company (US) 2005-02-02 — — EP disclosed
WO-2003088908-A2 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2003-10-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124435-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 CYP2C19 1758/4885MC4R 1501/4885ALDH1A1 656/4885
US-20240300938-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 CYP2C19 1758/4885MC4R 1501/4885ALDH1A1 656/4885
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 CYP2C19 1758/4885MC4R 1501/4885ALDH1A1 656/4885
US-20240400546-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 CYP2C19 1758/4885MC4R 1501/4885ALDH1A1 656/4885
US-12275723-B2 Compounds and uses thereof NLN, ACHE, CLN6 CYP2C19 1758/4885MC4R 1501/4885ALDH1A1 656/4885
US-11970486-B2 Compounds and uses thereof NLN, ACHE, CLN6 CYP2C19 1758/4885MC4R 1501/4885ALDH1A1 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.